Additional PET/CT Tracer to Detect Prostate Cancer
Researchers identify 18F-PMSA-1007 as an equally effective radiopharmaceutical for detecting prostate cancer.
Researchers have identified a second radiopharmaceutical that nuclear medicine departments can keep in mind when staging prostate cancer.
According to a study published in the April issue of the Journal of Nuclear Medicine, investigators in Israel determined 18fluorine prostate-specific membrane antigen-1007 (18F-PMSA-1007) can accurately pinpoint malignant prostate cancer lesions.
The team, led by Einat Evan-Sapir, M.D., Ph.D., from Tel Aviv Sourasky Medical Center, said this additional radiopharmaceutical likely has a longer half-life and better spatial resolution than 68gallium-PSMA-11 (68Ga-PMSA-11). According to the study details, 18F-PMSA-1007’s half-life is 110 minutes, and 68Ga-PMSA-11’s is 68 minutes. 68Ga-PSMA-11 also emits a higher-energy positron.
To determine efficacy, the team compared how well 18F- PMSA-1007 diagnosed prostate cancer to how well 68Ga-PSMA-11 performed with PET/CT scans. They evaluated 16 patients who were awaiting radical prostatectomy for newly-diagnosed intermediate- or high-risk prostate cancer. They, then, compared the outcomes with both radiopharmaceuticals with the gold standard of histopathologic findings.
Both 18F-PMSA-1007 and 68Ga-PMSA-11 identified the same location of radiolabeled PSMA-avid lesions in the prostate. However, 18F-PMSA-1007 pinpointed additional findings in four patients – three were confirmed as prostate cancer, and one was determined to be chronic prostatitis.
The results indicate an interchangeability between the radiopharmaceuticals, the team said.
“In view of the near-equal performance of the two traces, this preliminary study suggest the routine use of 18F-PMSA-1007 in lieu of 68Ga-PMSA-11 for staging prostate cancer patients, and clinicians can use either radiotracer based on availability,” the team wrote.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
